Related Experiment Video
Updated: Jul 12, 2026

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
Veratramine alleviates asthmatic airway remodelling via the PKM2/CREB1 lactylation/SMAD7 axis
Rixin Feng1, Qiaoyun Bai1, Ningpo Ding1
1Jilin Key Laboratory for Immune and Targeting Research on Common Allergic Diseases, Yanbian University, Yanji 133002, China; Department of Anatomy, Histology and Embryology, Yanbian University Medical College, Yanji 133002, China.
Background:
Veratramine is a natural steroidal alkaloid derived from plants of the genus Veratrum that exhibits anti-inflammatory potential. However, its pharmacological mechanisms and direct molecular targets in asthmatic airway remodelling remain unclear, particularly regarding its role in regulating metabolism-epigenetic crosstalk within the airway microenvironment.
Objective:
This study aimed to determine whether Veratramine downregulates pyruvate kinase M2 (PKM2) to suppress lactate accumulation, thereby inhibiting cAMP response element-binding protein 1 (CREB1) lactylation, restoring SMAD family member 7 (SMAD7) expression, and ultimately reversing transforming growth factor-β (TGF-β)-driven airway remodelling.
Methods:
A house dust mite (HDM)-induced murine asthma model was established to assess Veratramine efficacy. Molecular docking, molecular dynamics (MD) simulations, and cellular thermal shift assay (CETSA) confirmed its interaction with PKM2. Mass spectrometry, CUT&Tag sequencing, site-directed mutagenesis (K122R/Q), and adeno-associated virus (AAV)-mediated in vivo gene delivery were used to delineate the signalling axis.
Results:
Veratramine dose-dependently attenuated HDM-induced airway inflammation, goblet cell metaplasia, and subepithelial collagen deposition. It was shown to bind to and downregulate PKM2, thereby reducing pulmonary lactate accumulation. Mechanistically, HDM induced CREB1 lactylation at K122, limiting its conformational flexibility and promoting repression of the antifibrotic gene SMAD7, leading to TGF-β pathway activation and epithelial-mesenchymal transition (EMT). Inhibition of K122 lactylation or restoration of SMAD7 effectively reversed airway remodelling.
Conclusion:
This study identifies a novel "PKM2-lactate-CREB1 lactylation-SMAD7" axis driving airway remodelling in asthma. Veratramine acts as a PKM2 modulator, restoring SMAD7-mediated negative feedback via metabolic reprogramming, and represents a promising lead for anti-remodelling therapy.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
